A189 TREATMENT OF CHORNIC HEPATITIS C GENOTYPE 1 IN CANADA: REAL WORLD EXPERIENCE WITH OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN

Por Lee, S, Pinsonnault, C, Ackad, N, Landry, P
Publicado no J Can Assoc Gastroenterol (2018)

A223 MOSAIC: AN INTERNATIONAL MULTICENTRE PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE EPIDEMIOLOGY, HUMANISTIC AND ECONOMIC OUTCOMES OF TREATMENT FOR CHRONIC HEPATITIS C VIRUS...

Por Elkhashab, M, Ghesquiere, W, Lee, S, Shafran, S, Webster, D, Tam, E, Pinsonnault, C, Ackad, N
Publicado no J Can Assoc Gastroenterol (2018)

A188 REAL-LIFE MANAGEMENT OF CHRONIC HEPATITIS C VIRUS INFECTION IN CANADA: DESCRIPTION OF PATIENT PROFILE, PROGNOSTIC FACTORS AND TREATMENT STRATEGIES

Por Borgia, S, Elkhashab, M, Ghali, P, Kaita, K, Lee, S, Shafran, S, Tam, E, Trottier, B, Webster, D, Pinsonnault, C, Ackad, N
Publicado no J Can Assoc Gastroenterol (2018)